OncoSec Medical Incorporated, a biotechnology company, engages in developing DNA-based intratumoral immunotherapies in the United States. The company's investigational technology, ImmunoPulseis designed to enhance the local delivery and uptake of DNA-based immune-targeting agents, such as plasmid encoded IL-12 (tavokinogene telseplasmid or tavo) for the treatment of cancer. Its lead product candidate, ImmunoPulse IL-12, has demonstrated a favorable safety profile, evidence of anti-tumor activity in the treatment of various solid tumors, and the potential to reach beyond the site of local treatment to initiate a systemic immune response in Phase 1 and 2 clinical trials for metastatic melanoma and triple-negative breast cancer. The company has also completed Phase II studies in metastatic melanoma (OMS-I100) and merkel cell carcinoma (OMS-I110). OncoSec Medical Incorporated has an investigator-sponsored clinical trial with the University of California, San Francisco to evaluate the safety and efficacy of ImmunoPulse IL-12 in combination with KEYTRUDA (pembrolizumab) in patients with low tumor-infiltrating lymphocyte (OMS-I102); and a clinical trial collaboration and drug supply agreement with Merck (known as MSD outside the United States and Canada) to evaluate the combination of its ImmuoPulse IL-12 with Merck's anti-PD-1 therapy KEYTRUDA (pembrolizumab) in a registration-directed Phase 2b clinical trial referred to as PISCES. This trial would evaluate the combination of therapies in patients with unresectable metastatic melanoma who have progressed. It also has a research collaboration with Avacta Group plc for gene delivery of therapeutic affimers. The company was formerly known as NetVentory Solutions Inc. and changed its name to OncoSec Medical Incorporated in March 2011. OncoSec Medical Incorporated was incorporated in 2008 and is headquartered in San Diego, California.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:ONCS
CUSIPN/A
Phone855-662-6732
Debt
Debt-to-Equity RatioN/A
Current Ratio10.16
Quick Ratio10.16
Price-To-Earnings
Trailing P/E Ratio-1.31
Forward P/E Ratio-1.72
P/E GrowthN/A
Sales & Book Value
Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book Value$0.49 per share
Price / Book2.78
Profitability
EPS (Most Recent Fiscal Year)($1.06)
Net Income$-21,440,000.00
Net MarginsN/A
Return on Equity-155.69%
Return on Assets-125.35%
Miscellaneous
Employees35
Outstanding Shares52,350,000
OncoSec Medical (NASDAQ:ONCS) Frequently Asked Questions
What is OncoSec Medical's stock symbol?
OncoSec Medical trades on the NASDAQ under the ticker symbol "ONCS."
How were OncoSec Medical's earnings last quarter?
OncoSec Medical Inc (NASDAQ:ONCS) announced its quarterly earnings results on Wednesday, October, 25th. The biotechnology company reported ($0.28) earnings per share for the quarter, missing analysts' consensus estimates of ($0.23) by $0.05. View OncoSec Medical's Earnings History.
When is OncoSec Medical's next earnings date?
What price target have analysts set for ONCS?
4 brokerages have issued 12 month price targets for OncoSec Medical's shares. Their predictions range from $4.00 to $5.00. On average, they anticipate OncoSec Medical's stock price to reach $4.50 in the next twelve months. View Analyst Ratings for OncoSec Medical.
Who are some of OncoSec Medical's key competitors?
Some companies that are related to OncoSec Medical include Ocular Therapeutix (OCUL), Marinus Pharmaceuticals (MRNS), BioSpecifics Technologies (BSTC), Catalyst Biosciences (CBIO), Kadmon (KDMN), CTI BioPharma (CTIC), Ra Pharmaceuticals (RARX), Biofrontera (BFRA), Selecta Biosciences (SELB), Melinta Therapeutics (MLNT), Avadel Pharmaceuticals (AVDL), ASLAN PHARMACEUTICALS ADR REP 5 (ASLN), CELYAD SA/ADR (CYAD), Sierra Oncology (SRRA) and Cue Biopharma (CUE).
Who are OncoSec Medical's key executives?
OncoSec Medical's management team includes the folowing people:
- Dr. Avtar S. Dhillon, Co-Founder & Chairman (Age 57)
- Mr. Punit S. Dhillon BA, Co-Founder, Pres & Director (Age 38)
- Mr. Richard B. Slansky, CFO & Sec. (Age 60)
- Dr. Sharron Gargosky Ph.D., Chief Clinical & Regulatory Officer (Age 54)
- Mr. Daniel J. O'Connor J.D., CEO & Director (Age 54)
Has OncoSec Medical been receiving favorable news coverage?
Headlines about ONCS stock have been trending somewhat positive this week, Accern Sentiment reports. Accern scores the sentiment of news coverage by reviewing more than twenty million news and blog sources. Accern ranks coverage of companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. OncoSec Medical earned a media sentiment score of 0.07 on Accern's scale. They also gave news stories about the biotechnology company an impact score of 45.44 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the company's share price in the near term.
Who are OncoSec Medical's major shareholders?
OncoSec Medical's stock is owned by many different of retail and institutional investors. Top institutional shareholders include venBio Select Advisor LLC (7.78%), Point72 Asset Management L.P. (6.25%), Nexthera Capital LP (4.01%), Millennium Management LLC (1.94%), Commonwealth Equity Services LLC (0.15%) and DRW Securities LLC (0.14%). Company insiders that own OncoSec Medical stock include Daniel J O'connor and Punit Dhillon. View Institutional Ownership Trends for OncoSec Medical.
Which institutional investors are buying OncoSec Medical stock?
ONCS stock was acquired by a variety of institutional investors in the last quarter, including venBio Select Advisor LLC, Nexthera Capital LP, Point72 Asset Management L.P., Millennium Management LLC, DRW Securities LLC, Sofinnova Ventures Inc and Commonwealth Equity Services LLC. Company insiders that have bought OncoSec Medical stock in the last two years include Daniel J O'connor and Punit Dhillon. View Insider Buying and Selling for OncoSec Medical.
How do I buy shares of OncoSec Medical?
Shares of ONCS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is OncoSec Medical's stock price today?
One share of ONCS stock can currently be purchased for approximately $1.36.
How big of a company is OncoSec Medical?
OncoSec Medical has a market capitalization of $76.42 million. The biotechnology company earns $-21,440,000.00 in net income (profit) each year or ($1.06) on an earnings per share basis. OncoSec Medical employs 35 workers across the globe.
How can I contact OncoSec Medical?
OncoSec Medical's mailing address is 5820 NANCY RIDGE DRIVE, SAN DIEGO CA, 92121. The biotechnology company can be reached via phone at 855-662-6732 or via email at [email protected]
MarketBeat Community Rating for OncoSec Medical (ONCS)
MarketBeat's community ratings are surveys of what our community members think about OncoSec Medical and other stocks. Vote "Outperform" if you believe ONCS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ONCS will underperform the S&P 500 over the long term. You may vote once every thirty days.
